Arcturus Therapeutics provided a significant corporate update, announcing encouraging interim Phase 2 clinical data for its OTC deficiency candidate ARCT-810, introducing its next-generation LUNAR 2.0™ mRNA delivery platform, and revealing a definitive agreement to acquire AI discovery company myNEO.
Key Details
- ARCT-810 Phase 2 Data: Interim results for its Ornithine Transcarbamylase (OTC) deficiency therapeutic showed the drug was generally safe and well-tolerated, with encouraging activity across key biomarkers like ammonia and glutamine.
- LUNAR 2.0™ Platform: The new mRNA delivery platform demonstrated a greater than 30-fold improvement in protein expression in non-human primate studies. A new OTC candidate, ARCT-2601, utilizing this platform will be integrated into the ongoing Phase 2 study by year-end 2026.
- myNEO Acquisition: The company will acquire myNEO, an AI discovery firm, to improve its mRNA design and target identification capabilities. The transaction is expected to close in October 2026.